Azitra, Inc. - 8-K Filing
Azitra reported Q1 2026 financial results with a net loss of $3.9 million and cash balances of $10.1 million as of March 31, 2026. The company added MD Anderson Cancer Center to its Phase 1/2 trial for ATR-04 targeting EGFRi-associated skin rash and secured a new U.S. patent for lead candidate ATR-12 in Netherton syndrome. (Items: 2.02 and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended)
Tickers: $AZTR